110 related articles for article (PubMed ID: 8692534)
21. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
23. Mucinous tumors of the ovary: a review.
Hart WR
Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
[TBL] [Abstract][Full Text] [Related]
24. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
25. Benign, borderline, and well-differentiated malignant intestinal mucinous tumors of the ovary: a clinicopathologic, histochemical, immunohistochemical, and nuclear quantitative study of 57 cases.
de Nictolis M; Montironi R; Tommasoni S; Valli M; Pisani E; Fabris G; Prat J
Int J Gynecol Pathol; 1994 Jan; 13(1):10-21. PubMed ID: 8112952
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China.
Song W; Wu SJ; He YL; Cai SR; Zhang CH; Zhang XH; Zhan WH
Chin Med J (Engl); 2009 Jul; 122(13):1486-91. PubMed ID: 19719934
[TBL] [Abstract][Full Text] [Related]
27. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
28. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature.
Kolwijck E; Thomas CM; Bulten J; Massuger LF
Int J Gynecol Cancer; 2009 Nov; 19(8):1335-8. PubMed ID: 20009886
[TBL] [Abstract][Full Text] [Related]
29. Primary ovarian mucinous adenocarcinoma of intestinal type: a clinicopathologic study of 46 cases.
Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Siriaunkgul S
Int J Gynecol Pathol; 2014 Mar; 33(2):176-85. PubMed ID: 24487473
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma.
Nasioudis D; Chapman-Davis E; Witkin SS; Holcomb K
Gynecol Oncol; 2017 Feb; 144(2):414-419. PubMed ID: 27908528
[TBL] [Abstract][Full Text] [Related]
31. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
32. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma).
Koskas M; Uzan C; Gouy S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
Ann Surg Oncol; 2011 Jan; 18(1):40-8. PubMed ID: 20737216
[TBL] [Abstract][Full Text] [Related]
34. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
[TBL] [Abstract][Full Text] [Related]
35. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
[TBL] [Abstract][Full Text] [Related]
36. Borderline ovarian tumors: features and controversial aspects.
Messalli EM; Grauso F; Balbi G; Napolitano A; Seguino E; Torella M
Eur J Obstet Gynecol Reprod Biol; 2013 Mar; 167(1):86-9. PubMed ID: 23219291
[TBL] [Abstract][Full Text] [Related]
37. Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma.
Tian Q; Lu B; Ye J; Lu W; Xie X; Wang X
J Int Med Res; 2016 Apr; 44(2):357-66. PubMed ID: 26880793
[TBL] [Abstract][Full Text] [Related]
38. Ovarian mucinous tumors of low malignant potential: a clinicopathologic study of 54 tumors of intestinal and müllerian type.
Siriaunkgul S; Robbins KM; McGowan L; Silverberg SG
Int J Gynecol Pathol; 1995 Jul; 14(3):198-208. PubMed ID: 8600070
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic Features and Risk Factors for Recurrence of Mucinous Borderline Ovarian Tumors: A Retrospective Study With Follow-up of More Than 10 Years.
Sun L; Li N; Song Y; Wang G; Zhao Z; Wu L
Int J Gynecol Cancer; 2018 Nov; 28(9):1643-1649. PubMed ID: 30365456
[TBL] [Abstract][Full Text] [Related]
40. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
